Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) on behalf of Novavax stockholders. Our investigation concerns whether Novavax has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On October 19, 2021, after the market closed, Politico published an article, titled “’They Rushed the Process’: Vaccine Maker's woes hamper global inoculation campaign”, alleging manufacturing and purity problems in Novavax's process to produce Covid-19 vaccinations for COVAX, an international consortium working to provide two billion doses to middle and low income countries. Previously, the U.S. government invested $1.6B in Novavax in 2020, the most devoted to any vaccine manufacturer at the time.

On this news shares of Novavax fell over 20% in premarket trading on October 20, 2021.

If you purchased or otherwise acquired Novavax shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005555/en/